iRadimed (NASDAQ:IRMD) Releases Earnings Results, Beats Estimates By $0.02 EPS

iRadimed (NASDAQ:IRMD) issued its earnings results on Friday. The medical equipment provider reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02, FiscalAI reports. The firm had revenue of $20.47 million during the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed updated its FY 2026 guidance to 2.090-2.240 EPS and its Q3 2026 guidance to 0.540-0.590 EPS.

Here are the key takeaways from iRadimed’s conference call:

• Strong customer demand for the new 3870 pump drove bookings to more than double units shipped, with roughly 70% of replacement orders using four-channel quad systems and ASPs exceeding $110,000.
• IRadimed achieved its target of producing more than 130 3870 pumps in Q2 and plans to exceed 300 units in Q3, with startup costs expected to decline by more than 50% as manufacturing efficiencies improve.
• Q2 revenue was essentially flat year over year at $20.5 million, while gross margin fell to 74% from 78% and GAAP EPS declined to $0.41 from $0.45 due to the initial 3870 production ramp.
• Recurring revenue trends remained healthy, including 14% growth in disposables, while domestic patient-monitor sales reached a record 71 units and the company cited strong backlogs across pumps, monitors, and ferromagnetic detection systems.
• Management reaffirmed full-year 2026 guidance of $91 million–$96 million in revenue and $1.90–$2.05 in GAAP EPS, expects improving margins through the second half, and said a $100 million revenue run rate in Q4 is within reach.

iRadimed Price Performance

Shares of NASDAQ:IRMD traded down $4.35 during trading on Friday, hitting $90.86. 308,080 shares of the company were exchanged, compared to its average volume of 111,471. The stock has a market capitalization of $1.16 billion, a P/E ratio of 49.65 and a beta of 0.90. iRadimed has a 12-month low of $57.83 and a 12-month high of $107.90. The firm’s 50 day moving average price is $94.54 and its 200-day moving average price is $95.70.

iRadimed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 28th. Shareholders of record on Friday, August 14th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is presently 43.72%.

Key Headlines Impacting iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, iRadimed presently has an average rating of “Buy” and an average target price of $120.00.

Insider Activity

In related news, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $87.51, for a total value of $437,550.00. Following the transaction, the chief executive officer directly owned 2,175,000 shares of the company’s stock, valued at $190,334,250. This trade represents a 0.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 21,250 shares of company stock valued at $1,836,403. Corporate insiders own 34.60% of the company’s stock.

Institutional Investors Weigh In On iRadimed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada grew its holdings in shares of iRadimed by 14.7% during the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock worth $1,354,000 after buying an additional 3,307 shares during the last quarter. AQR Capital Management LLC increased its position in iRadimed by 7.5% in the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock valued at $831,000 after acquiring an additional 1,108 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in iRadimed by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after acquiring an additional 234 shares during the last quarter. Jones Financial Companies Lllp raised its stake in iRadimed by 8,568.5% during the 1st quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock valued at $591,000 after acquiring an additional 11,139 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in iRadimed by 1.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after acquiring an additional 1,821 shares during the period. 92.34% of the stock is owned by hedge funds and other institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.